|
[Related PubMed/MEDLINE]
Total Number of Papers: 99
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: CAM-DR |
| Long Form |
: cell adhesion-mediated drug resistance |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
Mechanisms of Cell Adhesion Molecules in Endocrine-Related Cancers: A Concise Outlook. |
CAMs |
| 2 |
2022 |
PI3K Targeting in Non-solid Cancer. |
ALL, BM, CLL |
| 3 |
2022 |
Significance of a tumor microenvironment-mediated P65-miR-30a-5p-BCL2L11 amplification loop in multiple myeloma. |
BMSCs, MM |
| 4 |
2022 |
Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple Myeloma. |
MM, MM niche, TNTs |
| 5 |
2022 |
Transformable ECM Deprivation System Effectively Suppresses Renal Cell Carcinoma by Reversing Anoikis Resistance and Increasing Chemotherapy Sensitivity. |
DOX, ECM, EDS, FN, RCC |
| 6 |
2021 |
Cadherins, Selectins, and Integrins in CAM-DR in Leukemia. |
AML, B- and T-ALL, CAMs, ECM |
| 7 |
2021 |
CAM-DR: Mechanisms, Roles and Clinical Application in Tumors. |
ECM |
| 8 |
2021 |
Extracellular Matrix Proteins Confer Cell Adhesion-Mediated Drug Resistance Through Integrin alpha v in Glioblastoma Cells. |
ECM, EGFR, GBM, MDR1, TF |
| 9 |
2021 |
In vitro and in vivo effects of AVA4746, a novel competitive antagonist of the ligand binding of VLA-4, in B-cell acute lymphoblastic leukemia. |
ALL, VCAM-1 |
| 10 |
2021 |
The expression of heat shock protein A12B (HSPA12B) in non-Hodgkin's lymphomas. |
BMSCs, FN, HSPA12B, NHL |
| 11 |
2020 |
ANXA7 promotes the cell cycle, proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L. |
ANXA7, CDC5L, CDK1, MM, PCNA |
| 12 |
2020 |
beta1-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters. |
ABC, COL1, FN, ITGB1 |
| 13 |
2020 |
CD49d and CD49e induce cell adhesion-mediated drug resistance through the nuclear factor-kappaB pathway in Burkitt lymphoma. |
Bax, Bcl-xL, Bim, BL, NF-kappaB |
| 14 |
2020 |
Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors. |
BMM, BMSCs, ECM, EM-DR, SM-DR |
| 15 |
2020 |
Effect of Wenxia Changfu Formula Combined With Cisplatin Reversing Non-Small Cell Lung Cancer Cell Adhesion-Mediated Drug Resistance. |
NSCLC, WCF |
| 16 |
2020 |
Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM). |
Co-IP, MM, PTB |
| 17 |
2020 |
Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP3R1/AKT/beta-catenin pathway. |
FN, TMZ |
| 18 |
2020 |
Runt-related transcription factor 2 influences cell adhesion-mediated drug resistance and cell proliferation in B-cell non-Hodgkin's lymphoma and multiple myeloma. |
B-NHL, MM |
| 19 |
2020 |
Upregulated expression and function of the alpha4beta1 integrin in multiple myeloma cells resistant to bortezomib. |
BM, BTZ, ITGB1, MM, OS, PFS, PIs |
| 20 |
2020 |
VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival. |
MMC, V-CP, V-NP, VLA4 |
| 21 |
2020 |
[Toll-like receptor CD180 and the bone marrow microenvironment as therapeutic targets in multiple myeloma]. |
BM, EZH2, LPS, MM |
| 22 |
2019 |
BTK induces CAM-DR through regulation of CXCR4 degradation in multiple myeloma. |
BTK, ECM, MM |
| 23 |
2019 |
EPHB6 mutation induces cell adhesion-mediated paclitaxel resistance via EPHA2 and CDH11 expression. |
CDH11, FAK, JNK |
| 24 |
2019 |
miR-182 contributes to cell adhesion-mediated drug resistance in multiple myeloma via targeting PDCD4. |
MM |
| 25 |
2019 |
Silencing of LIMD1 promotes proliferation and reverses cell adhesion-mediated drug resistance in non-Hodgkin's lymphoma. |
LIMD1, NHL |
| 26 |
2019 |
Targeting PI3K Signaling in Acute Lymphoblastic Leukemia. |
ALL, CLL |
| 27 |
2019 |
The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells. |
ILK, ITGB1 |
| 28 |
2018 |
Mechanisms of Matrix-Induced Chemoresistance of Breast Cancer Cells-Deciphering Novel Potential Targets for a Cell Sensitization. |
COL1, MX |
| 29 |
2018 |
[MicroRNA-138 regulates cell adhesion-mediated drug resistance phenotype by targeting SGTA in non-Hodgkin's lymphoma]. |
FN, NHL, SGTA |
| 30 |
2017 |
ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR). |
ARF1, FN, MM |
| 31 |
2017 |
CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. |
BM, BMSCs, MM |
| 32 |
2017 |
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. |
FAK, MCL |
| 33 |
2017 |
The PI3Kdelta Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL. |
ALL, FDA |
| 34 |
2017 |
Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma. |
NHL |
| 35 |
2016 |
Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells. |
CHD1L, FN, MM |
| 36 |
2016 |
Coadministration of the FNIII14 Peptide Synergistically Augments the Anti-Cancer Activity of Chemotherapeutic Drugs by Activating Pro-Apoptotic Bim. |
ECM |
| 37 |
2016 |
DIXDC1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) via enhancing p-Akt in Non-Hodgkin's lymphomas. |
DIXDC1, FN, NHL |
| 38 |
2016 |
Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. |
BMSCs, HDACs |
| 39 |
2016 |
Epigenetic regulation of cell adhesion-mediated drug resistance acquisition in multiple myeloma. |
--- |
| 40 |
2016 |
Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma. |
MM, VRK1 |
| 41 |
2016 |
Microenvironment drug resistance in multiple myeloma: emerging new players. |
DR, MM, SFM-DR |
| 42 |
2016 |
Notch1 controls cell chemoresistance in small cell lung carcinoma cells. |
KD, SCLC |
| 43 |
2016 |
RBQ3 participates in multiple myeloma cell proliferation, adhesion and chemoresistance. |
BMSCs, MM |
| 44 |
2016 |
Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma. |
CKIP-1, NHL |
| 45 |
2016 |
The cancer cell adhesion resistome: mechanisms, targeting and translational approaches. |
CAM-RR |
| 46 |
2016 |
The role of the Chaperonin containing t-complex polypeptide 1, subunit 8 (CCT8) in B-cell non-Hodgkin's lymphoma. |
CCT8, CCT8, NHL, RLH |
| 47 |
2016 |
The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells. |
MM, USP14 |
| 48 |
2016 |
Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma. |
DLBCL, FN, YB-1 |
| 49 |
2015 |
Cell adhesion down-regulates the expression of vacuolar protein sorting 4B (VPS4B) and contributes to drug resistance in multiple myeloma cells. |
MM, VPS4B |
| 50 |
2015 |
ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphomas. |
ENO1, NHLs |
| 51 |
2015 |
Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. |
EOC, HE4, IHC, OS, PFS |
| 52 |
2015 |
Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma. |
FN, NHL, TRIP6 |
| 53 |
2015 |
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. |
Bcl-2, HIF1A |
| 54 |
2015 |
Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance. |
MM, PKM2 |
| 55 |
2015 |
Sam68 regulates cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) via the AKT pathway in non-Hodgkin's lymphoma. |
CCK-8, NHL |
| 56 |
2015 |
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma. |
NHL |
| 57 |
2015 |
Upregulation of nuclear transporter, Kpnbeta1, contributes to accelerated cell proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse large B-cell lymphoma. |
DLBCL, Kpnbeta1 |
| 58 |
2015 |
[The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells]. |
--- |
| 59 |
2014 |
Expression of small glutamine-rich TPR-containing protein A (SGTA) in Non-Hodgkin's Lymphomas promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR). |
NHL, SGTA |
| 60 |
2014 |
Focal adhesion signaling and therapy resistance in cancer. |
CAM-RR, ECM |
| 61 |
2014 |
Gastric cancer cell adhesion to laminin enhances acquired chemotherapeutic drug resistance mediated by MGr1-Ag/37LRP. |
ECM |
| 62 |
2014 |
Histamine-releasing factor/translationally controlled tumor protein plays a role in induced cell adhesion, apoptosis resistance and chemoresistance in non-Hodgkin lymphomas. |
DLBCL, FL, FN, HRF, NHLs, NK |
| 63 |
2014 |
Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. |
BM, miR, MM, MSCs, ND |
| 64 |
2014 |
MGr1-Ag/37LRP induces cell adhesion-mediated drug resistance through FAK/PI3K and MAPK pathway in gastric cancer. |
--- |
| 65 |
2014 |
Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells. |
ECM, FN, OSCC |
| 66 |
2014 |
Role of integrin alpha4 in drug resistance of leukemia. |
ALL, BM, MRD |
| 67 |
2013 |
Adhesion to fibronectin induces p27(Kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells. |
FN |
| 68 |
2013 |
Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells. |
FN, MM, MRD |
| 69 |
2013 |
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. |
ATRA, HA |
| 70 |
2012 |
Extracellular matrix proteins modulate antimigratory and apoptotic effects of Doxorubicin. |
EMDR, SFM-DR |
| 71 |
2012 |
Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. |
DOX, MM, VLA-4 |
| 72 |
2012 |
Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. |
BM, ECM, FN, MM, VCAM-1 |
| 73 |
2011 |
Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. |
CAM-AR |
| 74 |
2011 |
Hammada scoparia flavonoids and rutin kill adherent and chemoresistant leukemic cells. |
--- |
| 75 |
2011 |
Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. |
FAK, ITGB7, MM |
| 76 |
2010 |
Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line. |
BMSCs, CML |
| 77 |
2009 |
Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. |
FN, IL, MM, STAT3 |
| 78 |
2009 |
ERK/MAPK activation involves hypoxia-induced MGr1-Ag/37LRP expression and contributes to apoptosis resistance in gastric cancer. |
ERK, MAPK |
| 79 |
2008 |
ANTI-ADHESION evolves to a promising therapeutic concept in oncology. |
CAM |
| 80 |
2008 |
Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. |
CXCR4, ICAM-1, MM, shRNA |
| 81 |
2008 |
HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. |
FN, HSPs, MM |
| 82 |
2008 |
Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. |
ECM, GBM |
| 83 |
2007 |
Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. |
AML, FN, MRD, VLA |
| 84 |
2007 |
The association of up-regulation of X-linked inhibitor of apoptosis protein with cell adhesion-mediated drug resistance in U937 cells. |
AML, FN, PI3K, XIAP |
| 85 |
2007 |
Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. |
--- |
| 86 |
2007 |
[Exploratory study of novel leukemia bone marrow stromal cell adhesion mediated drug resistance model]. |
BMSC |
| 87 |
2006 |
Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. |
--- |
| 88 |
2006 |
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. |
AML |
| 89 |
2006 |
Tumor microenvironment and drug resistance in hematologic malignancies. |
EM-DR, SM-DR |
| 90 |
2004 |
The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. |
BMSCs, Fpp, FTase, GGPP, GGTase, HMG-CoA, LFA-1, VLA-4 |
| 91 |
2003 |
Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. |
NF-kappaB |
| 92 |
2003 |
Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. |
--- |
| 93 |
2003 |
The tumor microenvironment: focus on myeloma. |
ECM |
| 94 |
2002 |
Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. |
--- |
| 95 |
2001 |
Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. |
CML, ECM, FN |
| 96 |
2001 |
The tumor microenvironment as a determinant of drug response and resistance. |
IL-6 |
| 97 |
2000 |
Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). |
ECM, FN |
| 98 |
2000 |
Integrin-mediated drug resistance in multiple myeloma. |
FN |
| 99 |
1999 |
Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. |
FN |
|
A Search Service for Abbreviation / Long Form
